Cidara Therapeutics Inc (CDTX)

Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

GlobeNewswire Inc.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

GlobeNewswire Inc.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

GlobeNewswire Inc.

Cidara Therapeutics Announces Reverse Stock Split

GlobeNewswire Inc.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire Inc.

TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates

Zacks Investment Research

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

GlobeNewswire Inc.

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

Zacks Investment Research

Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

GlobeNewswire Inc.

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

GlobeNewswire Inc.